CUTIA-B (02487) announced that a post-hoc analysis of its Phase III clinical trial in China evaluating the early efficacy of CU-10201 (topical 4% minocycline foam) in treating moderate-to-severe facial acne vulgaris has been selected for an oral presentation at the 20th Annual Conference of the Chinese Dermatologist Association (CDA) and National Conference on Cosmetic Dermatology.

CU-10201 is the first and only approved topical minocycline treatment for acne vulgaris globally, and the first topical minocycline to receive priority review and approval from China's National Medical Products Administration (NMPA). The 12-week efficacy and safety of CU-10201 for Chinese patients with moderate-to-severe acne vulgaris have been confirmed in Phase III clinical trials.

This post-hoc analysis assessed CU-10201's early efficacy during the first and second weeks of treatment in Chinese patients with moderate-to-severe facial acne vulgaris. Results demonstrated rapid onset of action, with significant improvement in inflammatory lesions observed as early as the first week, further enhanced by the second week. These findings highlight CU-10201's potential to provide fast symptom relief, offering important clinical benefits for acne vulgaris patients.